From 2022, journals will need to follow cOAlition S price transparency requirements to get paid. Find out more about the frameworks and potential benefits here.
Find out more about the principles of the Jussieu Call, which aims to promote bibliodiversity alongside open access in scientific publishing.
The latest State of Open Data survey results show changing trends in researchers’ attitudes towards the use of open data.
Scientific publishing is adapting to make research on COVID-19 and coronaviruses freely and rapidly available to all. But does the crisis highlight an opportunity for more fundamental reform?
Find out more about the TOP Factor, an alternative metric to the impact factor, evaluating academic journals based on open science policies.
PLOS ONE now offers Registered Reports, shifting peer review focus from results to the quality of study design. Is this part of the future of open science?
With widespread and growing support for increased data sharing, what can we learn from the Yale Open Data Access (YODA) Project and its collaboration with Johnson & Johnson?
Less than half of trials on clinicaltrials.gov meet the FDAAA results reporting deadline in a study from Ben Goldacre’s EBM DataLab at Oxford University
UNESCO uses this year’s World Science Day for Peace and Development to examine global disparities in open science.
Jackie Marchington, Director of Global Operations at Caudex, discusses good practice for conference abstracts and presentations
An analysis of data sharing statements reveals that open data may lead to a citation advantage.
A new tool from MPIP provides easily accessible information on open access options for industry-funded research.
Open source software is often used in science but is left uncited in many publications: researchers urge authors to make a change.
Researchers propose that self-organising peer review for preprints could be the future of scholarly publishing.
Discover the five areas for improvement identified in Springer Nature’s recent surveys of researchers, aiming to promote data sharing.
Many public funders have mandated open access to their research and support Plan S. Should pharmaceutical companies follow suit?